Navigation Links
Eftiar®-Octane

ProductsEftiar®-Octane
Company Dutch Ophthalmic, USA
Item Eftiar®-Octane
Features 
  • Naturally Pure
  • 100% Fluorinated and purified
  • Chemically inert liquid
  • Transparent, colorless and optically clear
  • Low refractive index
  • Clear differentiation
  • High specific gravity
  • Smooth flattening of a detached retina
  • Passive drainage of subretinal fluid
  • Chemically inert liquid
  • Low refractive index
  • High specific gravity
  • High vapor pressure allows evaporation of residual droplets
  • Specific gravity: 1,77 g/cm3 at 20 C
  • Refractive index: 1.27 at 20 C
  • Viscosity: 1,4 mPas at 25 C
  • Boiling point: 101,3-106 C
  • Packaging: 1 vial of 5 ml
Description Eftiar® offers the vitreoretinal surgeon a temporary tamponade for efficient re-attachment of the retina, release of subretinal fluid, dissection of fibro-vascular proliferation and controlling retinal bleeding. (Sterile, 5 ml. vail)
Info Dutch Ophthalmic, USACall Dutch Ophthalmic, USA to buy products (US and Canada only; other locations use number below) USACanada1-866-859-5660

Customer Service: (800) 75-DUTCH
Web site: http://www.dorc.nl/

Related medicine products :

1. Cochrane Reviews in Prostatic Diseases and Urologic Cancers
2. Acid Phosphatase, Prostatic
3. Prostatic Acid Phosphatase
4. Cypher Stent
5. Cypher Sirolimus-eluting Coronary Stent
6. MULTI-LINK OTW PIXEL Coronary Stent System
7. MULTI-LINK RX PIXEL Coronary Stent System
8. Express Coronary Stent System
9. NIR Elite OTW Stent System
10. S660 with Discrete Technology Coronary Stent System
11. NIR Elite Monorail Stent System
The name Silhouette stands for the power of an innovative idea. It all began in 1964 with just one designer, a staff of five and a novel, pioneering approach: eyewear was to be more than a simple imp
...ctural philosophy of the Kenneth Cole New York col...erning customer who appreciates luxury. The easy-t...th Cole New York accessories such as belts, handba...i-laminations craft the luminous handmade zyl. The...
...a memory metal segment under the Charmant brand. T...better fitting frame that's comfortable yet durabl...to bend or break won't faze CFX because it automat...rom classic to modern to sporty and is coupled wit...
The license agreement between Brook Brothers and Luxottica Group dates back to 1993. Characterized by lightweight materials and a slender line, the Brooks Brothers collections reflect the unique feat
Medicine Products:
(Date:9/5/2008)...., Sept. 5 /PRNewswire/ -- Arthrosurface, Inc.,( h...ss-invasive joint,resurfacing systems, announced t...begin its pivotal investigation for its line of fo... "there are no outstanding safety,concerns" with t...rosurface has been evaluating the safety and effic...
(Date:9/5/2008)...pt. 5 /PRNewswire-USNewswire/ -- U.S. citizens can... Cuban victims of Hurricane,Gustav, which is the w.../www.PanAmericanRelief.org ), "Donations will be ...ed,after this natural disaster," says Marc Wachten... at the Pan American Development Foundation, (http...
(Date:9/5/2008)...patients taking meds on Web site shouldn,t overrea... 5 (HealthDay News) -- The U.S. Food and Drug Admi...gs being evaluated for potential safety issues, th...a quarterly report, it means we have begun analysi...hat requires further evaluation," Dr. Gerald Dal P...
(Date:9/4/2008)....C. Free drug samples provided to physicians by p...uninsured patients more in the long run, according...versity Baptist Medical Center and colleagues. , ... habits of more than 70 physicians in a university...hs immediately before and after the closing of the...
Breaking Medicine News(10 mins):Health News:Arthrosurface HemiCAP(R) Focal Knee Resurfacing Implant Receives FDA Approval to Move into Final Investigational Stage 2Health News:Cuban Disaster Relief Donations Sought in the Wake of Hurricane Gustav 2Health News:FDA to List Drugs Under Review for Safety Issues 2Health News:Free drug samples may end up costing uninsured more 2Health News:Free drug samples may end up costing uninsured more 3
...’s Life of Life Healing Spa is increasingly gettin...ters of fat after the very first session. // Owner...ndergone the treatment with a good degree of succe...ire’ treatment when they opened in August. The fir...
...pecialists have expressed their disappointment ove...y have received transfusions of blood infected wit...t for this condition became available only in 1991...emophiliacs question the transfusion practice carr...
...d smoke has already been declared an air pollutant...onmental Protection Agency has also declared that ...esult of this, even though other groups like the C...n, the National Cancer Institute, and the American...
... William Honer and researchers have reported the r...cine in which they found in a trial conducted in 6...ntipsychotic drugs Clozapine and Risperdal for tre...s found that this combination drug did not work po...
Other Medicine News:
(Date:9/4/2008)...ort demonstrates potent antiviral activity and fav...e -, CAMBRIDGE, Mass., Sept. 4 /PRNewswire-FirstC...X ), a biopharmaceutical company engaged,in the di... of human viral,and other infectious diseases, tod...ncept study evaluating IDX899, a non-nucleoside re...
(Date:9/3/2008)... China, Sept. 3 /- Simcere,...facturer and supplier of,branded generic pharmaceu...r biotech product Endu (also known as Endostar) in...e IV clinical study., At the request of the SFDA,...rther validate the safety and therapeutic efficacy...
(Date:9/3/2008)...BURG, Md., Sept. 3 /- Panacea Pharmac.... Patent Number 7,413,737 covering,antibodies agai...(HAAH), a,proprietary human cancer biomarker and t... in collaboration with the Massachusetts Institute...rldwide rights to this patent,for development of h...
(Date:9/3/2008)...to be Evaluated in Repeat-Dosing Study in Subjects...FirstCall/ -- Sangamo,BioSciences, Inc. (Nasdaq: ...2 clinical trial (SB-509-801) to evaluate its drug...enerative motor-neuron disease for which there,are...s drug, SB-509, is an injectable formulation of a ...
Breaking Medicine Technology:Idenix Pharmaceuticals Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naive HIV-Infected Patients 2Idenix Pharmaceuticals Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naive HIV-Infected Patients 3Idenix Pharmaceuticals Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naive HIV-Infected Patients 4Simcere Pharmaceutical Group Announces Interim Results of Endu Phase IV Clinical Study 2Simcere Pharmaceutical Group Announces Interim Results of Endu Phase IV Clinical Study 3Panacea Pharmaceuticals Announces Issuance of a U.S. Patent Covering Anti-HAAH Antibodies 2Panacea Pharmaceuticals Announces Issuance of a U.S. Patent Covering Anti-HAAH Antibodies 3Panacea Pharmaceuticals Announces Issuance of a U.S. Patent Covering Anti-HAAH Antibodies 4Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 2Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 3Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 4Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 5GNC Schedules Conference Call and Webcast to Report Third Quarter 2007 Financial Results 5274 1Michael J Fox Foundation Commits Up to 242 Million for PD Drug Development Under Target Validation 2008 5269 1Michael J Fox Foundation Commits Up to 242 Million for PD Drug Development Under Target Validation 2008 5269 2Report shows less than half of kids in California are being read to daily 5266 1Report shows less than half of kids in California are being read to daily 5266 2Report shows less than half of kids in California are being read to daily 5266 3Elbit Medical Imaging Ltd Announces Results of Its Annual General Meeting 1656 1Elbit Medical Imaging Ltd Announces Results of Its Annual General Meeting 1656 2Elbit Medical Imaging Ltd Announces Results of Its Annual General Meeting 1656 3
...ainst Cancer-Causing Virus,Types 16 & 18 That ...ion Levels, CHICAGO, June 05, 2007 /PRNewswire/ --...he first of a three-dose regimen, 100,percent of w...ine,(GSK) cervical cancer candidate vaccine had an...r-causing human papillomavirus,types, 16 and 18. T...
... these data reassuring", PHILADELPHIA, June 05, 20...today that findings from an interim analysis,of RE... and,Regulation of glycemia in Diabetes), a prospe...rmine cardiovascular outcomes in more,than 4,400 p...e to,the overall cardiovascular safety profile of ...
Other Medicine Technology:Cervarix, the GSK Cervical Cancer Candidate Vaccine, Provides,Sustained Immune Response in 100 Percent of Women up to 55 Years of,Age 2Cervarix, the GSK Cervical Cancer Candidate Vaccine, Provides,Sustained Immune Response in 100 Percent of Women up to 55 Years of,Age 3Cervarix, the GSK Cervical Cancer Candidate Vaccine, Provides,Sustained Immune Response in 100 Percent of Women up to 55 Years of,Age 4Cervarix, the GSK Cervical Cancer Candidate Vaccine, Provides,Sustained Immune Response in 100 Percent of Women up to 55 Years of,Age 5Interim Data From RECORD Study Show No Significant Difference,Between Avandia and Standard Therapy in Risk of Cardiovascular,Hospitalization or Death 2Interim Data From RECORD Study Show No Significant Difference,Between Avandia and Standard Therapy in Risk of Cardiovascular,Hospitalization or Death 3Interim Data From RECORD Study Show No Significant Difference,Between Avandia and Standard Therapy in Risk of Cardiovascular,Hospitalization or Death 4Interim Data From RECORD Study Show No Significant Difference,Between Avandia and Standard Therapy in Risk of Cardiovascular,Hospitalization or Death 5